Finance entity
Johnson & Johnson is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. markets accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder. At 5.3, the average consequence score sits below the same-window beat average of 6.3.
Last mentioned: Aug 1, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Johnson & Johnson is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. markets accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder. At 5.3, the average consequence score sits below the same-window beat average of 6.3. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window. Across a 151-day span, the pace is roughly 0.2 stories per week. This profile follows 4 Finance stories mentioning AbbVie across the period from February 19, 2026 to July 19, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 3629 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AbbVie. Shared-story counts are live from our verified record — not editorial picks.
TD Cowen Conference
AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
DOJ Legal Support
The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
RBC Coverage Launch
RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
Humira Exclusivity Ends
The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.
The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Source: Cory Renauer (us) · fool.com
A new screening of high-conviction dividend stocks highlights leaders across healthcare, energy, and technology sectors. As investors seek defensive positioning, these seven companies represent a blend of dividend growth and capital preservation potential.
Source: themarketsdaily.com · tickerreport.com
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
AbbVie is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
